Company profile for Celltrion

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Celltrion stands as a prominent player in the Korean pharmaceutical landscape, accomplishing a feat once deemed improbable introducing the world's first "antibody biosimilar" from a nation with a comparatively less developed pharmaceutical sector. The company has boldly ventured into unexplored territories, achieving remarkable success. Building on this momentum, Celltrion is poised to further expand its footprint as a global ...
Celltrion stands as a prominent player in the Korean pharmaceutical landscape, accomplishing a feat once deemed improbable introducing the world's first "antibody biosimilar" from a nation with a comparatively less developed pharmaceutical sector. The company has boldly ventured into unexplored territories, achieving remarkable success. Building on this momentum, Celltrion is poised to further expand its footprint as a global biopharmaceutical entity, showcasing distinctive strategies in areas like small molecule pharmaceuticals and pioneering ventures such as the Ubiquitous healthcare platform business.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
South Korea
Address
Address
Yeonsu-gu, Incheon Metropolitan City
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251119058907/en/Celltrion-receives-Health-Canada-approval-for-Eydenzelt-a-biosimilar-referencing-Eylea-aflibercept-2mg

BUSINESSWIRE
27 Nov 2025

https://www.prnewswire.com/news-releases/celltrion-announces-publication-of-post-hoc-analysis-of-liberty-cd-study-of-zymfentra--infliximab-dyyb-indicating-consistent-efficacy-across-disease-location-including-the-terminal-ileum-in-clinical-gastroenterology-and-hepat-302626491.html

PR NEWSWIRE
26 Nov 2025

https://www.fiercepharma.com/manufacturing/celltrion-jacks-us-investment-plan-478m-outlay-upgrade-former-lilly-plant

FIERCE PHARMA
19 Nov 2025

https://www.fiercebiotech.com/biotech/celltrion-still-thinking-bigger-biosimilars-option-350m-antibody-deal

FIERCE BIOTECH
19 Nov 2025

https://www.businesswire.com/news/home/20251104874407/en/European-Commission-Grants-Approval-of-Remsima-IV-Liquid-Formulation-Worlds-First-Liquid-Formulation-of-IV-Infliximab

BUSINESSWIRE
18 Nov 2025

https://www.globenewswire.com/news-release/2025/11/04/3180471/0/en/Abpro-and-Celltrion-to-Present-Preclinical-Data-for-CT-P72-ABP-102-at-SITC-2025-Highlighting-a-Next-Generation-HER2-CD3-T-Cell-Engager.html

GLOBENEWSWIRE
04 Nov 2025

ABOUT THIS PAGE

Contact Celltrion and get a quotation

Celltrion is a supplier offers 3 products (APIs, Excipients or Intermediates).

Find a price of Infliximab bulk with JDMF offered by Celltrion

Find a price of Trastuzumab bulk with JDMF offered by Celltrion

Find a price of Infliximab bulk offered by Celltrion

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty